Merck & Co. is pruning its pipeline of antibody-drug conjugates (ADCs). Days after the Big Pharma paid $4 billion for three Daiichi Sankyo assets, Kelun-Biotech has revealed the Big Pharma has decided ...
LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback